Case study

Webinar: Analyzing vaccine purity – without an HCP ELISA

April 2023, by Ejvind Mortz

Analyzing vaccine purity

What did our LC-MS analyses of several mRNA- and protein-based vaccines for COVID-19 reveal?

A) it found that the product purity and HCP profiles vary substantially between marketed COVID-19 vaccines
B) it detected HCPs of potential concern in one of the vaccines

Join us to get examples of how you can unlock the knowledge necessary to achieve a consistent vaccine product - even within a short timeframe.

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
This field is for validation purposes and should be left unchanged.